The unique mechanism of fenfluramine at both serotonergic and Sigma1R targets8 may support fenfluramine as an add‐on therapy option to achieve clinically meaningful, durable reduction in seizure frequency and comorbidity management in patients with SCN8A‐epilepsy. The gene discussed is SCN8A; the disease is epilepsy.